Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00369733
Other study ID # 20010243
Secondary ID
Status Completed
Phase Phase 4
First received August 24, 2006
Last updated February 18, 2010
Start date May 2002
Est. completion date May 2004

Study information

Verified date February 2010
Source Amgen
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

To assess the effect of Aranesp on the hemoglobin (Hgb) of CRI subjects who are recombinant human erythropoietin (rHuEPO)-naïve or converting from rHuEPO therapy.


Description:

To assess the effect of Aranesp on the hemoglobin of CRI subjectswho are recombinant human erythropoetin (rHuEPO)-naïve or converting from rHuEPO therapy and to assess the association between subject self-reported health-related quality of life (HRQoL) as it relates to Hgb concentration and glomerular filtration rate (GFR) in subjects who were rHuEPO-naïve prior to study enrollment.

To characterize the health-related resource utilization of subjects with CRI. To characterize the subject satisfaction with Aranesp™ compared to previous rHuEPO therapy.

To characterize iron treatment in subjects with CRI. To evaluate the extent to which implementation of case management contributes to achieving the desired clinical objectives.

To assess the safety profile of Aranesp™ therapy in subjects with CRI.


Recruitment information / eligibility

Status Completed
Enrollment 443
Est. completion date May 2004
Est. primary completion date March 2004
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- diagnosis of CRI and not receiving dialysis therapy (must be predialysis)

- measured or estimated (using the Cockcroft-Gault formula) creatinine clearance (CrCl) of = 70 mL/min, or GFR = 60 mL/min (using the MDRD formula):

- Cockcroft-Gault formula: CrCl = (140 minus age in years) x (body weight in kg) serum creatinine (mg/dL) x 72.0. For women, the value will be multiplied by 0.85

- MDRD formula: GFR = 170 x [SCr]-0.999 x [Age]-0.167 x [0.762 if subject is female] x [1.180 if subject is black] x [SUN]-0.170 x [SAlb]-0.318

- (if subject is not already receiving rHuEPO therapy) mean Hgb < 11 g/dL during the screening/baseline period

- for subjects currently receiving rHuEPO therapy, the subject must have: a stable rHuEPO dose for the past month; and a rHuEPO frequency of once weekly.

- white blood cell and platelet counts within normal limits

- serum vitamin B12 and folate levels above the lower limit of normal range

- transferrin saturation (TSAT) = 20% during the screening period

- availability for follow-up assessments

- subject must be able to comprehend and be willing to, or have legally accepted representative, give written informed consent for participation in the study

Exclusion Criteria:

- scheduled to initiate dialysis

- uncontrolled hypertension (diastolic blood pressure > 105 mm Hg or systolic blood pressure of > 180 mm Hg during the screening/baseline period on two separate measurements)

- clinically unstable in the judgment of the investigator (eg, subject is in the intensive care unit, immediately post-myocardial infarction, etc)

- scheduled to receive a living donor kidney transplant

- treatment of grand mal epilepsy within the past 6 months

- moderate to severe congestive heart failure (NYHA class III or IV)

- clinical evidence of severe secondary hyperparathyroidism (parathyroid hormone level > 1500 pg/mL)

- severe active chronic inflammatory process (eg, ulcerative colitis, peptic ulcer disease, rheumatoid arthritis, etc)

- currently receiving antibiotic therapy for systemic infection (enrollment may be postponed until the course of antibiotics has ended)

- known aspartate aminotransferase (AST) or alanine aminitransferase (ALT) greater than 3 times the upper limit of the normal range on more than one occasion within three months prior to screening

- known positive HIV antibody or hepatitis B surface antigen

- clinical evidence of current malignancy and/or receiving chemotherapy with the exception of basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia

- active bleeding or RBC transfusion within eight weeks of enrollment

- androgen therapy within four weeks before enrollment

- known hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes, hematologic malignancy, myeloma; hemolytic anemia, etc)

- any condition that is likely to affect subject compliance

- currently or previously (within 30 days) enrolled in investigational device or drug trial(s) or receiving investigational agent(s)

- the exception to this is if the subject was enrolled in another Aranesp™ or rHuEPO protocol

- pregnant or breast feeding women (women of child-bearing potential must be using contraceptive precautions)

- women planning to have a child during the study period

- known hypersensitivity to the active substance or any of the excipients

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Darbepoetin alfa
Darbepoetin alfa adminstered SC every other week to acheive a Hb not to exceed 12 g/dL

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Amgen

Outcome

Type Measure Description Time frame Safety issue
Primary Mean hemoglobin during the evaluation period. 52 weeks No
Secondary Change in hemoglobin throughout the study 52 weeks No
Secondary HRQoL scores of rHuEPO-naïve subjects measured at baseline, week 12, week 24, and end of study 52 weeks No
Secondary Health-related resource utilization, measured every 4 weeks, throughout the study 52 weeks No
Secondary Patient satisfaction scores of subjects previously on rHuEPO therapy, measured at baseline and week 12 12 weeks No
Secondary Iron requirement (dose, frequency, and route) of subjects during the study 52 weeks No
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4